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Abstract
Background To identify predictive factors for improvement
of visual acuity and central retinal thickness by intravitreal
bevacizumab for the treatment of macular edema (ME) due
to branch retinal vein occlusion (BRVO).
Methods Two hundred and five eyes from 204 patients with
ME secondary to BRVO were retrospectively included at six
sites. All eyes received intravitreal bevacizumab therapy
(1.25mg/0.05ml).Themeanfollow-upwas36.8±12.7weeks
(range, 18 to 54 weeks). Measurement of ETDRS best-
corrected visual acuity (BCVA, in all eyes) and optical
coherence tomography (OCT, in 87% of eyes) were per-
formed at baseline and at follow-up examinations every
12 weeks. Using fluorescein angiography, the perfusion status
ofthemaculaatbaselinecouldbeassessedin84%oftheeyes.
The main outcome measures were changes in BCVA and
central retinal thickness (CRT). For analysis of predictive
factors, the results at 24 weeks were used.
Results The median BCVA was 0.6 LogMAR at baseline
and improved to 0.4 LogMAR at 24 and 48 weeks. This
visual improvement was associated by a significant reduc-
tion in CRT, decreasing from a baseline of 454 μmt o
267 μm and 248 μm after 24 and 48 weeks respectively.
Eyes with ME and intact (perfused) or interrupted (ische-
mic) foveal capillary ring showed a 2-line increase of
median BCVA [45 eyes (22%) and 128 eyes (62%)
respectively]. However, the final median BCVA was
significantly worse in eyes with ischemic ME (0.6 versus
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DOI 10.1007/s00417-010-1470-20.3 logMAR in perfused ME). Other factors for visual
improvement were absence of previous treatments of the
ME, age younger than 60 years and low baseline BCVA
(≥0.6 logMAR) (2, 3, and 2 median BCVA lines increase
respectively). Furthermore, eyes with duration of the ME of
less than 12 months responded with a 3-line increase of the
median BCVA. Final CRT only showed minor differences
between the subgroups. During the entire follow-up,
retreatments were performed in 85% of the eyes, with a
median number of injections of three (mean 3.2; range, 1 to
10) and a median time-interval between injections of
11.6 weeks (mean 14.6 weeks).
Conclusions Intravitreal injection of bevacizumab resulted in
a significant improvement of BCVA and reduction of ME in
BRVO. Baseline BCVA, patient’s age, and duration of BRVO
were found to be of prognostic relevance for visual
improvement. A less favorable outcome of the bevacizumab
therapy in eyes with longstanding BRVO would advocate
initiation of treatment within 12 months after onset.
Keywords Macular edema.Bevacizumab.Branch retinal
vein occlusion.Intravitreal therapy.Predictive factors.
Prognostic facotrs for visual improvement
Introduction
Secondary macular edema (ME) is one of the main reasons
for loss of visual acuity in branch retinal vein occlusion
(BRVO). The randomized, controlled Branch Vein Occlu-
sion Study showed limited treatment benefit in eyes with
perfused ME: Grid photocoagulation of the edematous
macula resulted in a better visual improvement than in the
natural course of the disease [1]. Actually, grid photocoag-
ulation was confirmed as the benchmark in a randomized
trial, with 29% of the eyes gaining 3 or more best corrected
visual acuity (BCVA) lines (≥15 letters) after 1 year.
Intravitreal injection of the corticosteroid triamcinolone
acetonide has not been shown to be more effective in
BRVO than grid photocoagulation [2] and efficacy of
intravitreal pegaptanib therapy is unclear [3]. Also, surgical
approaches including vitrectomy with or without peeling of
the inner limiting membrane [4], arteriovenous dissection
(sheathotomy) [5], laser-induced chorioretinal anastomosis
[6], and surgical cannulation of branch retinal veins [7]
failed to demonstrate a relevant benefit.
Therefore, a more efficacious treatment strategy has been
sought. Bevacizumab (Avastin®, Genentech, San Francisco,
CA, USA) is a humanized monoclonal antibody directed
against the vascular endothelial growth factor (VEGF). The
rationale for its intravitreal application in BRVO was that
vascularocclusioninducesupregulationofVEGF,resultingin
increased vascular permeability and subsequent ME 8–10.
Recently, various clinical studies demonstrated benefi-
cial effects of anti-VEGF therapy on both ME and BCVA in
patients with BRVO [11–18]. Moreover, this minimally
invasive therapy might be even more effective than grid
photocoagulation, which is the current standard of care. A
prospective study on previously untreated eyes with
perfused ME secondary to BRVO demonstrated a gain of
3 or more BCVA lines in 57% at 1 year [14]. However, the
significance of previous studies was limited, due to the
relatively small sample sizes. In addition, the optimal time
point for initiation of therapy remains unclear. More
importantly, there is still minimal knowledge concerning
predictive factors for visual outcome.
Because of the large number of patients included, this is
the first study to permit a detailed subgroup analysis. This
made it possible to investigate various potential predictive
factors, including macular perfusion status, duration of the
ME, patients’ age, baseline BCVA, number of injections
applied, and previous treatments before intravitreal bevaci-
zumab therapy in clinical practice.
Subjects and methods
The study was designed as a multicenter retrospective
analysis of patients that received intravitreal bevacizumab
therapy for the treatment of BRVO associated with a ME
involving the foveal center. Patients received the first
bevacizumab injection between October 2005 and May
2009. Only patients that finished the follow-up examination
at 24 weeks were included. Eyes that had undergone
vitrectomy prior to bevacizumab treatment were excluded
due to the different pharmacokinetics. Eyes with other
diseases affecting BCVA or presence of neovascularisation
were excluded from the analysis. If patients had received
peripheral, focal or grid laser photocoagulation, cyclo-
destructive interventions, cataract surgery, or other surgical
procedures during the follow-up they were also excluded.
Baseline examination comprised a complete eye exam-
ination, including ETDRS BCVA, slit-lamp biomicroscopy,
dilated fundus examination, and optical coherence tomog-
raphy (OCT) in most eyes. To assess the perfusion status of
the macula, preservation (perfused ME) or capillary drop-
out of the foveal capillary ring (ischemic ME) [1],
fluorescein angiographies at baseline were analyzed. In
case of hemorrhages in the macular area that obscured
the foveal capillary ring, the perfusion status was not
evaluated until resorption of these hemorrhages was seen.
Only retina specialists experienced in the analysis of
fluorescence angiograms were in charge of the analysis in
each center.
The study followed the tenets of the Declaration of
Helsinki, and was approved by the local ethics committees
at each site.
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The intravitreal injection was performed according to the
recommendation of the German Retina Society [19]. The
injections were performed after topical anaesthesia and
preoperative antisepsis with povidon iodine using sterile
gloves, drape, and a lid speculum. Bevacizumab (Avastin®)
1.25 mg in a 0.05 ml total volume was injected intra-
vitreally via the pars plana. Following the injection, retinal
perfusion was controlled.
All patients were informed about the nature of off-label
use and the experimental nature of the therapy before signing
an informed consent prior to each injection. Also, they
confirmed that they were aware of the potential side-effects
of bevacizumab treatment. Patients with contraindications
against an intravitreal bevacizumab injection (acute ocular
infection, recent history of stroke or myocardial infarction,
unstable angina pectoris, uncontrolled hypertension, uncom-
pensated renal insufficiency, allergy to bevacizumab, or
pregnancy) were excluded from treatment [20].
Follow-up
Patients were followed on a routine clinical program.
Follow-up examinations at 12, 24, 36 and 48 weeks
(±6 weeks) were analyzed. The main outcome measures of
this study were BCVA and central retinal thickness (CRT) as
measuredbyOCT(StratusOCT
TM, Carl Zeiss Meditec, Jena,
Germany, axial tissue resolution 10-15 μm, or Spectralis®
OCT, Heidelberg Engineering, Dossenheim, Germany, axial
tissue resolution 4 μm). To minimize variability between
different devices, all patients were followed up with the same
OCT. CRT was calculated as the distance between the inner
limiting membrane and the retinal pigment epithelium–
choriocapillaris interface of radial lines through the foveal
area [21]. The foveal area was determined using the patient’s
fixation and retinal landmarks. The calipers were set by hand
because automated measurement protocols are more prone to
errors [22]. For comparison, the normal CRT in healthy eyes
was reported to be 170 ± 18 μm[ 23].
Re-injection was considered at each follow-up visit, and
performed after informed consent of the patient, depending
on the individual course of the BCVA and persistence or
reoccurence of ME on OCT.
Statistics
VA data were converted to logMAR units before analysis.
All continuous variables (BCVA and CRT) were described
as box plots showing 5% and 95% quantiles (whiskers),
25% and 75% quartiles (box), and the median (marked by
an asterisk). While conventional statistical inference in this
study is based on sample means, we use median values as a
robust index of the sample's central tendency for descriptive
report of the data.
The following prognosticvariables were studied:perfusion
status of the foveal capillary ring (ischemic or perfused),
existence of pre-treatment, patients’ age (younger than
60 years or 60 years and older), duration of BRVO
(<3 months, 3 to 12 months, or >12 months), baseline BCVA
(0.6 logMAR and lower or 0.5 logMAR and higher), number
of injections applied (one, two or three and more), gender
(male or female), and presence of arterial hypertension.
Overall differences in VA and CRTat 0, 12, and 24 weeks
were assessed using repeated measures analysis of variance
(ANOVA). Subgroup-specific changes in VA and CRTwere
analyzed using paired t-tests (two-sided). Significant prog-
nostic factors for an increase in VA were identified by
between-subjects multifactorial ANOVA and Tukey’s HSD
post-hoc tests where appropriate. Further differences be-
tween subgroups were analyzed using unpaired t-tests, and
between-subjects ANOVAs in the case of more than two
subgroups. To control for multiple comparisons, Bonferroni
correction was applied with respect to the overall number of
tests for VA and CRT differences respectively (VA: eight
tests, CRT: eight tests), resulting in adjusted significance
thresholds of p=0.00625 All statistical analysis was
performed using SPSS 16 (SPSS Inc, Chicago, IL, USA).
Results
This multicenter, retrospective interventional case series
enrolled 205 eyes (204 patients) of six centres that were
treated with intravitreal bevacizumab due to ME secondary
to BRVO. Patient characteristics at baseline are shown in
Table 1. The median follow-up was 36.7 weeks (range, 18
to 54 weeks; mean 36.8±12.7 weeks). The median age of
the patients was 69 years (range, 38 to 87 years). The
bevacizumab treatment resulted in a significant improve-
ment of the median BCVA (ANOVA p<0.001), increasing
from 0.6 logMAR at baseline to 0.5 logMAR at 12 weeks
and 0.4 logMAR at 24 weeks (both p’<0.001). Ninety-one
eyes (44.4%) finished the final follow-up examination at
48 weeks. They showed a maintenance of the median
BCVA of 0.4 logMAR corresponding to a total improve-
ment of 2 median BCVA lines compared to baseline (p<
0.001, Fig. 1a). OCT data were available in 91%, 82%,
and 87% of all eyes at baseline, 12, and 24 weeks,
respectively. Accordingly, reduction of the CRT was
highly significant with the median CRT (ANOVA p<
0.001) decreasing from a baseline of 454 μmt o3 0 4μm
and 267 μm after 12 and 24 weeks, respectively (both p<
0.001). This significant reduction was preserved over the
Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192 185entire follow-up with a final median CRT of 248 μma t
1 year (63 eyes, p<0.001, Fig. 1b). During the follow-up,
a median of three injections (mean 3.2; range, 1 to 10) was
administered, with a median injection frequency of
11.6 weeks (mean 14.6 weeks).
Analysis of predictive factors
Because BCVA and CRT did not significantly change
between 24 and 48 weeks (Fig. 1a,b), analysis of predictive
factors was performed on the basis of the 24 weeks results
of all 205 eyes included.
Evaluation of the perfusion status of the macular area
revealed an ischemic ME with a broken foveal capillary
ring in 22% (45 eyes) and a perfused ME in 62% (128
eyes). Sufficient information on the perfusion status was
not available in 16% (32 eyes) (Table 1). Interestingly, both
subgroups with perfused and ischemic ME improved 2
median BCVA lines at 24 weeks (both p<0.001). However,
eyes with an ischemic ME started from a lower median
baseline BCVA of 0.8 logMAR compared to 0.5 logMAR
of the subgroup with a perfused ME (p<0.001). Hence,
their final median BCVA of 0.6 logMAR at 24 weeks was
significantly lower than 0.3 logMAR in eyes with a
perfused ME (p<0.001) (Fig. 2a). Comparing the baseline
and final median CRT in the two subgroups, there was no
Table 1 Predictive factors for visual improvement (at 24 weeks)
Factor Number
of eyes
Increase of
median
BCVA lines
P value
(increase)
Final
median
BCVA
(logMAR)
ANOVA
(p
value)
Gender 0.83
Male 101
(49%)
2 <0.001 * 0.4
Female 104
(51%)
2 <0.001 * 0.4
Hypertension 0.89
Yes 131
(64%)
2 <0.001 * 0.4
No 69
(34%)
2 <0.001 * 0.4
Perfusion status of the macula 0.95
Ischemic 45
(22%)
2 <0.001 * 0.6
Perfused 128
(62%)
2 <0.001 * 0.3
Pretreatment 0.86
Yes 26
(13%)
0.5 <0.005 0.5
No 176
(86%)
2 <0.001 * 0.4
Patients' age (years) <0.01 *
<60 41
(20%)
3 <0.001 * 0.3
≥60 163
(80%)
1 <0.001 * 0.5
Baseline BCVA (logMAR) <0.001
*
≤0.5 91
(44%)
1 <0.001 * 0.3
≥0.6 114
(56%)
2 <0.001 * 0.6
Duration of BRVO (months) 0.03 *+
<3 63
(31%)
2.5 <0.001 * 0.3
3-12 71
(35%)
2 <0.001 * 0.4
>12 60
(29%)
0.5 <0.01 0.5
Number of injections 0.48
14 6
(22%)
2.5 <0.001 * 0.35
27 9
(39%)
2 <0.001 * 0.5
≥37 4
(36%)
2 <0.001 * 0.4
* = Significant difference (Bonferroni-corrected)
+ = Post-hoc test (Tukey–HSD): <3 months and >12 months sign.
difference)
Fig. 1 Box plot graphs showing the course of best-corrected visual
acuity (BCVA) (a) and central retinal thickness (CRT) (b) over the
48 weeks follow-up. a Increase of BCVA, and b, decrease of the CRT
following bevacizumab treatment. Note the stabilisation after
24 weeks. n = number of eyes included
186 Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192Fig. 2 Box plot graphs showing the bevacizumab effect depending on
the duration of the perfusion status of the macula (a, b), on the
existence of pretreatment (c, d), on the patients’ age (e, f), and on the
baseline visual acuity (VA) (g, h) during the 24 weeks follow-up. Left
column demonstrates the course of the BCVA, the right column shows
the central retinal thickness (CRT)
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and perfused ME (baseline: 500 μm and 450 μm( p=0.04,
n.s.); 24 weeks: 266 μm and 250 μm( p=0.44, n.s.)
respectively) (Fig. 2b).
Pretreatment had been undertaken in 13% (26 eyes);
23 eyes had undergone grid laser photocoagulation, and
seven eyes had received intravitreal triamcinolone injection
prior to bevacizumab treatment. Eighty-six percent (176
eyes) received bevacizumab as a primary therapy for BRVO
(Table 1). Interestingly, the pretreated subgroup only
showed a visual improvement of 0.5 median BCVA lines
from a median of 0.55 logMAR to 0.5 logMAR at 24 weeks
(p<0.005, Fig. 2c), and no reliable decrease of the median
CRT from 350 μm at baseline to 274 μm at 24 weeks (p=
0.113, Fig. 2d). In contrast, the previously untreated eyes
responded with a 2-line increase of the median BCVA (0.6
logMAR to 0.4 logMAR, p<0.001, Fig. 2c), together with a
reduction of the CRT (463 μm to 266 μm, p<0.001,
Fig. 2d). The duration of the BRVO-associated symptoms
was significantly longer in the pretreated subgroup, with
21.4 months versus 4.3 months in previously untreated eyes
(p<0.005).
Analysis of the patients’ age at the time of BRVO
confirmed it as a significant prognostic factor for gain in
BCVA (multi-factorial ANOVA, p<0.001), with a better
response in younger individuals (Table 1). The subgroup of
patients who were younger than 60 years of age (41 eyes,
20%) revealed a considerable 3-line increase of the median
BCVA (from 0.6 logMAR at baseline to 0.3 logMAR at
24 weeks, p<0.001). In contrast, patients of 60 years and
older (163 eyes, 80%) only showed a gain of 1 median BCVA
line (from 0.6 logMAR at baseline to 0.5 logMAR at
24 weeks), which was statistically significant, p<0.001,
Fig. 2e). This is despite the fact that the median CRT of
younger and older patients was not significantly different,
neither at baseline (463 μmc o m p a r e dt o3 5 0μm, p=0.86),
nor at 24 weeks (260 μmc o m p a r e dt o2 7 5μm, p=0.70)
(Fig. 2f). However, the median duration of BRVO prior to
bevacizumab therapy was significantly shorter in younger
individuals (3.0 months; range, 0.0 to 75 months) than in
older individuals (6.5 months; range, 0.0 to 163 months) (p<
0.05). Moreover, in the younger subgroup, only 5% (two
eyes) had received pretreatment (intravitreal triamcinolone
injection), compared to 15% (24 eyes) in the older subgroup.
To investigate the prognostic value of the baseline
BCVA, the eyes were divided into two subgroups with a
BCVA≥0.6 logMAR (range: 0.6 to 2.0 logMAR, 114 eyes)
and≤0.5 logMAR (range, 0.1 to 0.5 logMAR, 91 eyes)
before treatment. Our data showed that eyes with a low
baseline BCVA gained median 2 BCVA lines (from 0.8
logMAR to 0.6 logMAR, p<0.001), whereas eyes with a
high initial BCVA only gained median 1 VA line (from 0.4
logMAR to 0.3 logMAR, p<0.001) (Fig. 2g). Multi-
factorial ANOVA confirmed baseline BCVA as a signifi-
cant prognostic factor for BCVA gain (p<0.001, Table 1).
Comparing the percentage of ischemic ME and hemorrhage
in the foveal area in the two subgroups, both were
considerably higher in the cohort with a low baseline
BCVA (32% and 37% versus 10% and 17%). Also, the
median baseline CRT was higher in eyes with a low initial
BCVA compared to eyes with a high initial BCVA (501 μm
versus 348 μm, p<0.001). However, both subgroups
improved their median CRT at 24 weeks to comparable
levels (270 μm and 266 μm respectively, p=0.43) (Fig. 2h).
The median time between the onset of BRVO-associated
symptoms and the baseline examination was 5.7 months
(range, 0.0 to 163 months). The onset of BRVO-associated
symptoms remained unclear in 5% (11 eyes) (Table 1). To
evaluate the impact of early treatment on BCVA and ME,
the eyes were assigned to one of three subgroups according
to the duration of BRVO prior bevacizumab therapy: group
A <3 months (63 eyes), group B 3 to 12 months (71 eyes),
and group C >12 months (60 eyes). Multi-factorial ANOVA
confirmed duration of BRVO-associated symptoms as a
significant prognostic factor for BCVA gain (p=0.03), with
a significantly higher gain for group A than for group C
(p<0.05, Tukey HSD). Interestingly, subgroup A showed a
significant gain of 2.5 median BCVA lines from a median
baseline of 0.65 logMAR to 0.3 logMAR at 24 weeks
(p<0.001), whereas the visual improvement in group B was
2 median BCVA lines (from 0.6 to 0.4 logMAR, p<0.001).
In contrast, subgroup C only showed a 0.5 line increase of
the median BCVA, from 0.55 to 0.5 logMAR at 24 weeks
(p=0.005) (Fig. 3a). Hemorrhage in the foveal area at
baseline was present in 45% (28 eyes) of group A, in 34%
(24 eyes) of group B, and in 7% (four eyes) of group C.
With regard to the median CRT at 24 weeks, there was no
significant difference between the three groups (A 273 μm,
B 260 μm, and C 290 μm, p=0.86) even though at baseline
significant differences were evident (ANOVA p<0.05);
Baseline CRT was significantly higher in group A, 483 μm
compared to 400 μm in group C (p<0.05 Tukey HSD) and
472 μm in group B, Fig. 3b).
To maintain the bevacizumab effect until week 24, re-
injections were performed in 75% (153 eyes). During the
6-month follow-up, a median of two injections (mean 2.3;
range, 1 to 6) was administered, with a median time-
interval between injections of 11.5 weeks (mean
14.8 weeks). The relationship between the bevacizumab
effect and the number of injections was analyzed, assigning
the eyes to a subgroup with one, two or three and more
injections. Interestingly, the BCVA showed comparable
results in all three subgroups, with an increase of the
median BCVA of 2.5 lines (one injection) or 2 lines (two
and ≥3 injections) (ANOVA p=0.27, Fig. 3c). When
comparing the median CRT at baseline and at 24 weeks
188 Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192between the three subgroups, they were lowest in the subset
with only one injection (345 and 224 μm), and increased
with more injections (two injections: 472 and 271 μm;
three and more injections: 454 and 296 μm, both ANOVA
p<0.05) (Fig. 3d). For the group of three or more injections
(74 eyes) we analysed if there is a correlation between the
number of injections and BCVA or CRT. However, the
analysis revealed no significant correlation (p>0.05),
neither for BCVA nor for CRT.
As the number of eyes included in the analysis varied
across parameters (from 173 to 205, Table 1)w ep e r f o r m e d
an additional analysis on a subset of eyes where the
complete data of all essential parameters (perfusion status
of the macula, pretreatment, patients' age, baseline BCVA,
duration of BRVO, and number of injections) was available.
This subset of eyes included 158 eyes. Comparably, multi-
factorial ANOVA confirmed patients’ age (p<0.001), base-
line BCVA (p<0.001), and duration of macular edema (p=
0.05) as significant prognostic factors for BCVA gain
(Table 2).
As eyes with central glaucomatous visual field defects
and diabetic maculopathy were excluded from our study,
the percentage of eyes with glaucoma and diabetes (7%
and 10%, respectively) was likely to be underestimated,
and therefore was not part of the analysis of predictive
factors.
No cases of endophthalmitis, retinal detachment or any
other severe procedure-related complications were observed
in a total of 652 injections. No obvious bevacizumab-
related ocular or systemic adverse events were reported.
Discussion
This multicentre study examined the anatomic and func-
tional long-term effectiveness of bevacizumab therapy on
ME secondary to BRVO in a routine clinical setting.
Previously, several prospective studies have shown a
significant 3-line increase of BCVA together with a
reduction of ME [14–16]. Our study shows that comparable
results can also be obtained in the clinical routine. In this
large patient cohort, a significant increase of the median
BCVA of 2 lines was achieved at the 6-month follow-up,
and could be maintained through the 1-year follow-up.
Together with results from other reported studies, intra-
vitreal bevacizumab may appear as an established treatment
for ME secondary to BRVO [14, 18]. However, clinical
practice has also revealed that some patients respond better
Fig. 3 Box plot graphs showing the bevacizumab effect depending on
the duration of the BRVO-associated symptoms (a, b), and on the
number of injections applied (c, d) during the 24 weeks follow-up.
Left column demonstrates the course of the visual acuity (VA), the
right column shows the central retinal thickness (CRT)
Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192 189than others, while factors for the variability in outcomes have
been controversial. Due to the large sample size, this is the
first study that allows analyzing potential predictive factors in
detail to pre-estimate the effectiveness of the therapy.
A point of intense debate is the influence of the
perfusion status of the macula on treatment outcomes.
While the beneficial effect of bevacizumab in eyes with ME
and perfused foveal capillary ring seems to be generally
acknowledged, concerns have been raised on bevacizumab
treatment in ischemic ME [8, 24]. Also, grid photocoagu-
lation has not been recommended for BRVO with foveal
capillary nonperfusion [1].
Our study was able to demonstrate for the first time that
existence of an ischemic ME can still be associated with an
excellent response to bevacizumab therapy. These eyes
showed both a pronounced reduction of the CRT and a
considerable visual improvement of 2 lines, comparable to
the visual improvement in eyes with perfused ME. This
interesting finding seems to be in contrast to previous
studies. Chung et al. reported the presence of macular
ischemia as a significant negative factor for BCVA
improvement. The investigation was done on 50 eyes
subdivided into two groups (≥1B C V Al i n eg a i nv s
<1 BCVA line gain) [25]. However, analysis in our cohort
revealed BCVA gain in about 70% of the eyes in both
ischemic (69%) and perfused ME (73%), indicating a
potential for BCVA improvement in ischemic ME.
How can we explain the apparent discrepancy between
the significant BCVA gain in eyes with ischemic macular
edema and the clinical observation that these patients rarely
achieve a satisfactory post-treatment BCVA? One should
take into account that eyes with ischemic ME disclose a
low baseline BCVA, which prevents most eyes to achieve
reading visual acuity even if the treatment response is good.
Irreversible structural changes induced by persisting hyp-
oxia in the centre of the macula have been identified as the
reason behind this observation [8]. Patient satisfaction is
not solely determined by gain in BCVA line, but rather by
achieving useful vision. Hence, many patients with ische-
mic ME remain disappointed despite the remarkable 2-line
gain. On the other hand, patients with perfused ME seem to
be more satisfied with a 2-line BCVA gain because of the
high rate of reading ability achieved.
Another important question addresses the optimal time
point for initiation of bevacizumab therapy. The Branch
Vein Occlusion Study showed a worse BCVA outcome in
eyes where the treatment with grid laser photocoagulation
had been performed more than 1 year after onset of the
BRVO [1]. Comparable findings have been described for
intravitreal bevacizumab therapy [12, 16]. Our study
confirmed these results showi n gn os i g n i f i c a n tv i s u a l
improvement in longstanding ME of more than 1 year.
Photoreceptor damage as a result of chronic ME has been
proposed to explain the irreversible BCVA impairment [8].
In contrast, eyes with duration of BRVO shorter than
1 year showed a 2-line BCVA increase. Moreover, further
shortening of the initiation of therapy resulted in a further
improvement of the outcome. Here, a very early treatment
(<3 months) revealed an increase of 2.5 BCVA lines and a
remarkable final BCVA of 0.3 logMAR. This might
indicate some irreversible damage to the macula following
delayed treatment, which has also been proposed by Kondo
and colleagues [18]. However, absorption of hemorrhages
in the foveal area that are frequently apparent in the
subgroup of very early treatment might be a cofactor for the
Table 2 Predictive factors for visual improvement at 24 weeks
(subgroup of 157 eyes)
Factor Number
of eyes
Increase of
median
BCVA lines
P value
(increase)
Final
Median
BCVA
(logMAR)
ANOVA
(p
value)
Perfusion status of the macula 0.97
Ischemic 40
(25%)
3 <0.001 * 0.6
Perfused 117
(75%)
1 <0.001 * 0.4
Pretreatment 0.86
Yes 21
(13%)
0 =0.018 0.5
No 136
(87%)
2 <0.001 * 0.4
Patients' age (years) <0.001
*
<60 33
(21%)
3 <0.001 * 0.3
≥60 124
(79%)
1 <0.001 * 0.5
Baseline BCVA (logMAR) <0.001
*
≤0.5 68
(43%)
1 =0.029 0.3
≥0.6 89
(57%)
2 <0.001 * 0.6
Duration of BRVO (months) 0.05 *+
<3 50
(32%)
2.5 <0.001 * 0.35
3-12 54
(34%)
2 <0.001 * 0.4
>12 53
(34%)
1 =0.011 0.5
Number of Injections 0.34
14 1
(26%)
1 <0.001 * 0.5
26 2
(40%)
2 <0.001 * 0.5
≥35 4
(34%)
2 =0.001 * 0.4
* = Significant difference (Bonferroni-corrected)
+ = Post-hoc test (Tukey–HSD): no significant pair-wise differences
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course of the disease independent of the bevacizumab effect
might play a significant role.
In addition to the duration of BRVO, the patient's age
has been identified as a prognostic factor. We were able to
demonstrate that patients under 60 years of age respond
with a 3-line increase of BCVA. Additionally, these eyes
develop a high final BCVA of 0.3 logMAR. However, in
the younger subgroup the median duration of BRVO was
shorter, and fewer eyes had undergone pretreatment,
accounting for a better bevacizumab response. However, a
correlation of age and BCVA has also been found recently
by a prospective study [17]. On the other hand, patient age
of 60 years and older was associated with minor visual
improvement, despite a comparable reduction of the CRT.
One might conclude from these data that the anatomical
response does not seem to be an appropriate clinical tool for
evaluating the treatment benefit. Eyes with poor prognostic
factors develop a poor visual outcome, despite the fact that
these eyes often show a marked reduction of CRT.
Baseline BCVA has also been identified as a predictive
factor for visual improvement. In accordance with previous
studies [18], we found a poor baseline BCVA (>0.5
logMAR) to be correlated with poor visual prognosis below
reading BCVA. Frequent associations with a poor baseline
BCVA were presence of an ischemic ME and hemorrhage
in the foveal area. Vice versa, a good initial BCVA (≤0.5
logMAR) was significantly associated with a good visual
outcome. In contrast to previous findings [24], our study
demonstrates a remarkable visual improvement of 2 BCVA
lines in eyes with a poor baseline, even exceeding the
visual improvement in eyes with a high initial BCVA. A
negative correlation of preoperative VA and improvement
of VA has also been shown in a current study [18]. The
pronounced reduction of the CRT in patients with low
baseline BCVA compared to eyes with high baseline BCVA
is in accordance with the findings of Kriechbaum and
colleagues [16].
Existence of pretreatment has been identified as a
negative factor for visual improvement. Eyes with a
persistent ME after pretreatment responded with no
significant increase of the BCVA to the bevacizumab
treatment, despite an excellent reduction of the CRT.
However, as pretreatment was correlated with very long-
standing ME, this might also account for a worse treatment
effect. Due to the small sample number, our results are
limited, though a reduced prognosis for BCVA improve-
ment and final BCVA in pretreated eyes was also described
in previous studies [11, 15].
Another question that is frequently raised addresses the
number of re-injections needed to maintain the treatment
effect. In our study, we found a mean injection rate of 2.3
injections within 6 months and a mean of 3.2 during the
entire follow-up. A prospective study recently reported
similar injection rates, with a mean of 2.6 and 3.4 injections
within the first 6 or 12 months respectively, resulting in an
increase of 3 BCVA lines [14]. Taking into account the fact
that our current study has been performed on a clinical
routine basis that did not adhere to strict retreatment
criteria, and even included eyes with pretreatment and
long-standing ME, the current results are remarkably
comparable.
Is a more frequent re-injection rate beneficial? Another
prospective study performed an OCT-guided treatment
regime with a mean of eight injections during a 12-month
follow-up, which resulted in a 3.5-line increase in BCVA
[13]. This indicates that a higher injection rate above a
critical level does not result in a further increase of the
treatment effect. Accordingly, we could not find a better
visual improvement with increased numbers of bevacizu-
mab injections. Our study rather demonstrates a slightly
higher final median CRT despite frequent re-injections
indicating non-responders.
One of the most notable results of our study concerns the
effect of bevacizumab on the ME. Independent of the
median baseline CRTof all subgroups (345 μm to 501 μm),
and independent of the bevacizumab effect on the BCVA,
the treatment resulted in a decrease of the CRT to a median
CRT ranging from 224 to 296 μm (250 to 275 μm except
for the subgroups with duration of BRVO of more than
12 months, and number of injections of one and three or
more) at 6 months. This indicates that the effect of
bevacizumab on the ME is not a reduction by a certain
percentage, but rather a decrease to a defined median CRT
around 260 μm. Therefore, it appears necessary to adjust
the re-injection rate to the individual course of the BCVA
and CRT on OCT.
Main limitations of this study were the retrospective
character, the inconsistent reinjection criteria, and the
absence of a control group. The drawback of the variable
number of eyes across parameters included in the subgroup
analysis was counterbalanced by the second subgroup
analysis with a homogeneous data set revealing basically
comparable results. However, a prospective, randomized
study is needed to further assess the effectivity of
bevacizumab on various subgroups. However, this is the
first study with a sufficient number of patients included to
permit the identification of predictive factors in a routine
clinical treatment setting.
Based on more than 650 intravitreal injections in this
study, no concerns on the safety of the drug emerged. This
is especially important in view of the off-label use and the
necessity for repeated injections in most eyes.
As duration of the BRVO of more than 1 year seems to
result in a negligible effect of bevacizumab, earlier
treatment initiation might be reasonable. This study data
Graefes Arch Clin Exp Ophthalmol (2011) 249:183–192 191could be important for understanding the effect of bevaci-
zumab on BCVA and ME, and to manage individual
treatment regimes for eyes with BRVO.
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